Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

York University

$25,000.00

Development of a mass spectrometry-enabled assay for the identification of new cellular targets for antibody-drug conjugates that utilize a novel payload delivery mechanism

EF 2015-16

Résumé
ImmunoBiochem has developed a disruptive technology that will revolutionize the field of Antibody-Drug Conjugate (ADC) therapeutics. ADCs comprise a novel class of targeted therapeutics that combine the high specificity of monoclonal antibodies with highly-potent chemotherapeutic small-molecule drugs, and are able to selectively and efficaciously deliver a toxic payload to cancer cells. ImmunoBiochems next-generation ADCs for oncology utilize a novel approach that enables the targeting of solid tumors based on intracellular tumor antigens or cancer biomarkers that are considered undruggable and inaccessible to targeted biological therapeutics. ImmunoBiochems lead ADCs, IMB-101 and IMB-102, are targeted at an undisclosed intracellular tumor antigen that is a clinically-validated cancer biomarker, and offer superior selectivity for cancer cells compared to conventional receptor-targeted ADCs. IMB-101 and IMB-102 thus offer a superior safety profile and broad therapeutic window, preventing on-target toxicities against normal, healthy cells that are common with many ADCs, including the clinically approved ADC, trastuzumab DM1 (Kadcylar). IMB-101 and IMB-102 are being developed for Triple-Negative Breast Cancer (TNBC), an aggressive disease for which no targeted biological therapeutic treatment options are currently available. The proposed work will enable ImmunoBiochem to leverage academic expertise in mass spectrometry and quantitative onco-proteomics to develop and validate an assay for the discovery of new cellular targets for ADC therapeutics that can take advantage of ImmunoBiochems new payload delivery mechanism.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
491958-2015
Name nom
Wilson, Derek
Department département
Chemistry
Organization id
38
Institution établissement
York University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Partie
1
Nb partie
1
Application title
Development of a mass spectrometry-enabled assay for the identification of new cellular targets for antibody-drug conjugates that utilize a novel payload delivery mechanism
Keyword
NSERC
Application summary
ImmunoBiochem has developed a disruptive technology that will revolutionize the field of Antibody-Drug Conjugate (ADC) therapeutics. ADCs comprise a novel class of targeted therapeutics that combine the high specificity of monoclonal antibodies with highly-potent chemotherapeutic small-molecule drugs, and are able to selectively and efficaciously deliver a toxic payload to cancer cells. ImmunoBiochems next-generation ADCs for oncology utilize a novel approach that enables the targeting of solid tumors based on intracellular tumor antigens or cancer biomarkers that are considered undruggable and inaccessible to targeted biological therapeutics. ImmunoBiochems lead ADCs, IMB-101 and IMB-102, are targeted at an undisclosed intracellular tumor antigen that is a clinically-validated cancer biomarker, and offer superior selectivity for cancer cells compared to conventional receptor-targeted ADCs. IMB-101 and IMB-102 thus offer a superior safety profile and broad therapeutic window, preventing on-target toxicities against normal, healthy cells that are common with many ADCs, including the clinically approved ADC, trastuzumab DM1 (Kadcylar). IMB-101 and IMB-102 are being developed for Triple-Negative Breast Cancer (TNBC), an aggressive disease for which no targeted biological therapeutic treatment options are currently available. The proposed work will enable ImmunoBiochem to leverage academic expertise in mass spectrometry and quantitative onco-proteomics to develop and validate an assay for the discovery of new cellular targets for ADC therapeutics that can take advantage of ImmunoBiochems new payload delivery mechanism.